Brief: Santhera Says NXERA Plans To Submit South Korea Marketing Authorization Application 2026
02/06/2026 07:58
BRIEF-Santhera Says NXERA Plans To Submit South Korea Marketing Authorization Application 2026 June 2 (Reuters) - Santhera Pharmaceuticals Holding AG SANN.S:
SANTHERA ANNOUNCES ORPHAN DRUG AND PRIORITY REVIEW DESIGNATIONS FOR AGAMREE® (VAMOROLONE) IN SOUTH KOREA
SANTHERA PHARMACEUTICALS - GIFT DESIGNATION MAY SHORTEN REVIEW TIMELINE TO 90 WORKING DAYS IN SOUTH KOREA
SANTHERA PHARMACEUTICALS : NXERA PLANS TO SUBMIT A MARKETING AUTHORIZATION APPLICATION IN SOUTH KOREA DURING 2026
Source text: ID:nGNX5NQxk
Further company coverage: SANN.S
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Nxera Pharma
See all newsNxera Pharma Submits Marketing Authorization Application For Vamorolone In South Korea For Treatment Of Duchenne Muscular Dystrophy
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up
Brief: Nxera Pharma - Entered Into Exclusive License, Supply And Commercialization Agreement With Synmosa For Quviviq Across Eight Asia-Pacific Markets
Brief: Nxera Announces Successful Resolution Of Minig Patent Infringement Action
Factbox: Weight-loss drug developers line up to tap lucrative market as competition heats up